8-K: Beyond Air Reports FY26 Results and Fiscal Year Shift

Beyond Air reported 107% annual revenue growth to $7.7 million and announced a transition to a December 31st fiscal year-end.

Summary

• Fiscal year 2026 revenue reached $7.7 million, a 107% increase over the prior year.
• Fiscal fourth quarter 2026 revenue was $1.9 million, up 66% year-over-year.
• The company is changing its fiscal year-end from March 31 to December 31, effective December 31, 2026.
• Net loss for fiscal 2026 was $33.2 million, compared to a $46.6 million loss in fiscal 2025.
• The company holds $17.3 million in cash, cash equivalents, and marketable securities as of March 31, 2026.
• Revenue guidance for calendar year 2026 is set at $8 million, with 2027 guidance projected at $16-$18 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive update; while revenue growth is strong and operational efficiency is improving, the company remains loss-making and faces significant regulatory and capital-related risks.

Positives

• Annual revenue grew 107% year-over-year to $7.7 million.
• Gross profit turned positive at $0.25 million for fiscal 2026, compared to a $1.66 million loss in 2025.
• Operating expenses decreased significantly, with R&D down 39% and SG&A down 27% year-over-year.
• Secured a third major U.S. group purchasing organization (GPO) agreement.
• Expanded global distribution network to over 45 countries.

Negatives

• Reported a net loss of $33.2 million for fiscal 2026.
• Net cash burn for the fiscal year was $19.1 million.
• Long-term debt stands at $21.6 million as of March 31, 2026.
• Quarterly net loss increased to $10.3 million from $8.0 million in the same quarter last year.
• The company is currently not in compliance with Nasdaq's minimum bid price rule.

Risks

• Dependence on FDA approval for the second-generation LungFit PH system.
• Potential inability to raise additional capital if required.
• Risks associated with the unproven nature of developing novel nitric oxide therapies.
• Competition from other companies using similar technology.
• Potential for regulatory delays in international markets.

Future Outlook

The company expects $8 million in revenue for calendar year 2026 and projects $16-$18 million for 2027, driven by the anticipated launch of the second-generation LungFit PH system.

Management Comments

• Fiscal 2026 was a year of meaningful transition, marked by significant progress in strengthening the foundation of our LungFit PH commercial program.
• We are encouraged by the market interest in the second-generation LungFit PH system, which is currently under FDA review.
• If approved, we believe the addressable market opportunity for the LungFit platform could increase by 4X in the United States to approximately $400 million.

Industry Context

StockSavvy.ai notes that Beyond Air is attempting to pivot from a high-burn R&D phase to a commercial-scale growth phase. The shift in fiscal year-end is a common administrative move for companies aligning their reporting with calendar-year cycles to improve comparability with peers in the medical device sector.

Comparison to Industry Standards

• Revenue growth of 107% significantly outpaces typical growth rates for established medical device companies, though it is off a smaller base.
• The company's reliance on a single platform (LungFit) presents higher concentration risk compared to diversified med-tech conglomerates.
• The transition to a December 31 fiscal year-end aligns the company with the majority of U.S. public companies, facilitating easier benchmarking.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Impacted by the 1-for-20 reverse stock split intended to maintain Nasdaq listing.
• Customers: Benefit from expanded GPO access and potential new product features pending FDA approval.
• Employees: Affected by prior restructuring and cost-reduction initiatives.

Next Steps

• Regain compliance with Nasdaq Bid Price Rule by July 31, 2026.
• Await FDA approval for the second-generation LungFit PH system.
• File transition report on Form 10-K/T for the nine-month period ending December 31, 2026.

Key Dates

Recommendation

The company is at a critical inflection point with high revenue growth but significant cash burn and regulatory dependency. Investors should wait for FDA approval of the Gen 2 device and evidence of sustained cash flow improvement before increasing exposure.

Keywords

Beyond Air, XAIR, Nitric Oxide, LungFit, Medical Device, Respiratory Therapy, Biopharmaceutical